Conditions: Autistic Disorder
Keywords: Lactobacillus reuteri autistic disorder microbiome
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 15
Healthy volunteers: no

Brief summary:
SB-121 is being developed for use in the treatment of autistic disorder (AD).

This study is a multiple-dose, randomized, double-blind, placebo-controlled, cross-over single-site Phase I study.

The primary objective is to evaluate the safety and tolerability of multiple doses of SB-121 in subjects ages 15 to 45 years with AD.

Additionally, multiple measures of AD, as well as mechanistic biomarkers, will be assessed in order to inform later stage trials.

Detailed description:

Arms:
arm 1: One dose of SB-121 daily for 28 days according to the treatment group to which they are allocated.

Administration: Oral arm 2: One dose of placebo daily for 28 days according to the treatment group to which they are allocated.

Administration: Oral

Interventions: intervention 1: SB-121 intervention 2: Placebo
Intervention descriptions: intervention 1: SB-121 is a formulation of L. reuteri intervention 2: Placebo oral formulation

Protocol document:
Prot_000.pdf: 
Document Type: 
Final Protocol 
Document Date:  
Version 4 – 15 October 2021 
Study Title:  
Randomized, Double-blind, Placebo-controlled, 28-Day Daily-dose 
Crossover Study of the Safety and Tolerability of SB-121 
(Lactobacillus reuteri with Sephadex® and Maltose) in Subjects, ages 
15 to 45 years, diagnosed with Autistic Disorder 
Protocol Reference Number:  SBI-SB121-20-01 
NCT Number:  
NCT04944901 

































































































































SAP_001.pdf: 
Document Type:  
Final Statistical Analysis Plan 
Document Date:   
Version 1 – 20 January 2022 
Study Title:  
Randomized, Double-blind, Placebo-controlled, 28-Day Daily-dose 
Crossover Study of the Safety and Tolerability of SB-121 
(Lactobacillus reuteri with Sephadex® and Maltose) in Subjects, ages 
15 to 45 years, diagnosed with Autistic Disorder 
Protocol Reference Number:  SBI-SB121-20-01 
NCT Number:  
NCT04944901 
 
 
 


Statistical Analysis Plan Version 1.0 
 
CONFIDENTIAL 
 
 
Protocol Reference: SBI-SB121-20-01 
 
 
Final, Version 1.0, 20Jan2022 
Page 1 of 28 
 
 
ST-AD-008 version 06 
 
 
Statistical Analysis Plan  
Randomized, Double-blind, Placebo-controlled, 28-Day Daily-dose 
Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus 
reuteri with Sephadex® and Maltose) in Subjects, ages 15 to 45 years, 
diagnosed with Autistic Disorder 
 
Statistical Analysis Plan: Final 
Statistical Analysis Plan: 1.0 
Statistical Analysis Plan Date: 20Jan2022 
Investigational Product: SB-121 
Protocol Reference: SBI-SB121-20-01 
  
Sponsor: Scioto Biosciences Inc. 
 
 
 
Author: 
 Principal Biostatistician 
 
 
 
 
 
 
 
Information described herein is confidential and may be disclosed only with the express written 
permission of the sponsor. 


Statistical Analysis Plan Version 1.0 
 
CONFIDENTIAL 
 
 
Protocol Reference: SBI-SB121-20-01 
 
 
Final, Version 1.0, 20Jan2022 
Page 2 of 28 
 
 
ST-AD-008 version 06 
 
Table of Contents 
Reviewers ................................................................................................................................. 4 
Glossary of Abbreviations ....................................................................................................... 4 
1. Source Documents ............................................................................................................... 5 
2. Protocol Details .................................................................................................................... 6 
2.1. Overall Study Design .................................................................................................... 6 
2.2. Study Objectives ........................................................................................................... 6 
2.2.1. Primary Objective(s) ............................................................................................... 6 
2.2.2. Secondary Objective(s) ........................................................................................... 7 
2.3. Sample Size and Power ................................................................................................. 7 
2.4. Primary Efficacy Variable(s) ........................................................................................ 7 
2.5. Secondary Efficacy Variable(s) .................................................................................... 7 
2.6. Exploratory Efficacy Variable(s) .................................................................................. 7 
2.7. Safety Variable(s) .......................................................................................................... 7 
3. Estimand(s) .......................................................................................................................... 8 
3.1. Estimands for the primary / secondary  objective(s) ..................................................... 8 
4. Analysis Populations ............................................................................................................ 9 
4.1. All Screened Population ................................................................................................ 9 
4.2. Intent-to-Treat Population ............................................................................................. 9 
4.3. Safety Population .......................................................................................................... 9 
5. Data Handling .................................................................................................................... 10 
5.1. Time Points and Visit Windows.................................................................................. 10 
5.1.1. General Definitions............................................................................................... 10 
5.1.2. Screening / Baseline Period .................................................................................. 10 
5.1.3. Treatment Period .................................................................................................. 10 
5.1.4. Visit Windows ...................................................................................................... 11 
5.2. Handling of Dropouts, Missing Data, and Outliers ..................................................... 11 
5.2.1. Handling of Missing Efficacy Data ...................................................................... 11 
5.2.2. Handling of Missing Safety Data ......................................................................... 11 
5.2.3. Handling of Partial and Missing Dates for Adverse Events, Prior / Concomitant 
Medications .................................................................................................................... 11 


Statistical Analysis Plan Version 1.0 
 
CONFIDENTIAL 
 
 
Protocol Reference: SBI-SB121-20-01 
 
 
Final, Version 1.0, 20Jan2022 
Page 3 of 28 
 
 
ST-AD-008 version 06 
 
6. Statistical Methods ............................................................................................................. 13 
6.1. General Principles ....................................................................................................... 13 
6.2. Subject Disposition and Data Sets Analyzed .............................................................. 13 
6.3. Protocol Deviations ..................................................................................................... 14 
6.4. Demographic and Other Baseline Characteristics ....................................................... 15 
6.4.1. Demographic Characteristics ................................................................................ 15 
6.4.2. Baseline Characteristics ........................................................................................ 15 
6.4.3. Medical History .................................................................................................... 16 
6.4.4. Prior and Concomitant Medications ..................................................................... 16 
6.5. Measurements of Treatment Compliance ................................................................... 17 
6.6. Efficacy ....................................................................................................................... 18 
6.6.1. Primary Efficacy Analysis .................................................................................... 18 
6.6.2. Secondary Analysis .............................................................................................. 18 
6.7. Safety ........................................................................................................................... 19 
6.7.1. Extent of Exposure ............................................................................................... 19 
6.7.2. Adverse Events ..................................................................................................... 19 
6.7.3. Laboratory Evaluations ......................................................................................... 22 
6.7.4. Vital Signs ............................................................................................................ 23 
6.7.5. Electrocardiograms ............................................................................................... 24 
6.7.6. Physical Examination ........................................................................................... 24 
6.7.7. Interim Analysis and Data Monitoring ................................................................. 24 
6.8. Pharmacokinetic Assessments..................................................................................... 25 
7. Changes in the Conduct of the Study or Planned Analysis ............................................... 26 
8. References .......................................................................................................................... 28 
 
 
 






Statistical Analysis Plan Version 1.0 
 
CONFIDENTIAL 
 
 
Protocol Reference: SBI-SB121-20-01 
 
 
Final, Version 1.0, 20Jan2022 
Page 6 of 28 
 
 
ST-AD-008 version 06 
 
2. Protocol Details 
2.1. Overall Study Design 
This is a phase 1, single-center, randomized, double-blind, placebo-controlled, cross-
over study to evaluate the safety and tolerability of 28-days of once daily oral 
administration of SB-121 (a preparation of L. reuteri with Sephadex® and maltose), to 
subjects with autistic disorder (AD). 
 
Up to 16 eligible subjects will be randomized 1:1 to receive treatment with either SB-
121 or placebo for 28 days. After a washout period of approximately 14 days, the 
subjects will be crossed over to the alternate treatment for approximately 28 days. 
 
Subjects will undergo screening within approximately 14 days before the first 
administration of the investigational product (IP). All subjects (or parent/authorized 
designee) will be required to provide written informed consent before any study-specific 
procedures are performed. Subjects will also be asked to provide consent to allow 
storage of biological samples for future analysis that will not involve genetic tests. 
Subjects’ eligibility for the study will be determined at Screening by assessment of 
inclusion and exclusion criteria. Eligible subjects will be provided with a stool sampling 
kit to collect a pretreatment stool sample within 48 hours before receiving the IP. 
 
Subjects will return to the study site (clinic) on Day 1. Following confirmation of 
eligibility criteria, they will be randomized to receive SB-121 or placebo. Following 
baseline tests, all subjects will be given their first dose of either SB-121 or placebo at the 
clinic. 
 
Subjects will undergo study-specific procedures on Day 1 in accordance with the 
schedule of events and will be discharged after all Day 1 evaluations have been 
completed. They will then take the IP at home once a day for the remaining 
approximately 27-days. They will then return to the clinic on Day 28. 
 
Following the approximately 14 day washout period, all subjects will cross-over to the 
other treatment (SB-121 or placebo) for approximately 28-days and the study procedures 
will be repeated. 
 
Follow-up clinic visits will be conducted on Day 28 of Treatment Period 1, Day 1 of 
Treatment Period 2, and Day 28 of Treatment Period 2. 
 
2.2. Study Objectives 
2.2.1. Primary Objective(s) 
To evaluate the safety and tolerability of multiple doses of SB-121 in subjects with AD 
 


Statistical Analysis Plan Version 1.0 
 
CONFIDENTIAL 
 
 
Protocol Reference: SBI-SB121-20-01 
 
 
Final, Version 1.0, 20Jan2022 
Page 7 of 28 
 
 
ST-AD-008 version 06 
 
2.2.1.1. Estimands for the Primary Objective(s) 
Not applicable 
 
2.2.2. Secondary Objective(s) 
 To monitor the elimination of Sephadex® from the GI tract in subjects with AD 
 To assess the impact of multiple doses of SB-121 on circulating oxytocin levels in 
subjects with AD 
 To assess the impact of multiple doses of SB-121 on tests of AD 
 To evaluate biomarkers of microbiota function, immune modulation, and 
inflammation following multiple doses of SB-121 in subjects with AD 
 
2.2.2.1. Estimands for the Secondary Objective(s) 
Not applicable 
 
2.3. Sample Size and Power 
The sample size was not determined based on statistical assumptions. Evaluation of up 
to 8 subjects per treatment group (16 subjects total) was considered sufficient to allow 
evaluation of the study’s objectives. 
 
2.4. Primary Efficacy Variable(s) 
The main objective of this study is to evaluate safety and tolerability of SB-121. There 
are no primary efficacy variables to assess. 
 
2.5. Secondary Efficacy Variable(s) 
Secondary efficacy variables include circulating oxytocin levels, tests of AD, and 
biomarkers of microbiota function, immune modulation, and inflammation. 
 
2.6. Exploratory Efficacy Variable(s) 
Not applicable 
 
2.7. Safety Variable(s) 
Safety variables include: Incidence and severity of treatment-emergent AEs (TEAEs), 
serious AEs (SAEs), AESIs, and AEs leading to discontinuation from the study; 
incidence of presence of Sephadex® microspheres in the stool: incidence of symptomatic 
bacteremia with positive L. reuteri identification. Additionally,  clinical laboratory 
values that are abnormal and considered clinically significant, vital signs, and abnormal 
physical examination results will be evaluated. 


Statistical Analysis Plan Version 1.0 
 
CONFIDENTIAL 
 
 
Protocol Reference: SBI-SB121-20-01 
 
 
Final, Version 1.0, 20Jan2022 
Page 8 of 28 
 
 
ST-AD-008 version 06 
 
3. Estimand(s) 
3.1. Estimands for the primary / secondary  objective(s) 
Not applicable 


Statistical Analysis Plan Version 1.0 
 
CONFIDENTIAL 
 
 
Protocol Reference: SBI-SB121-20-01 
 
 
Final, Version 1.0, 20Jan2022 
Page 9 of 28 
 
 
ST-AD-008 version 06 
 
4. Analysis Populations 
In accordance with ICH E3 and E91, the following analysis sets will be used for the analyses. 
 
4.1. All Screened Population 
The All Screened population will consist of all subjects screened. It will be used for 
summary and listing of screen failures. 
 
4.2. Intent-to-Treat Population 
The Intent-to-Treat population (ITT) will consist of all randomized subjects who signed the 
informed consent form. ITT subjects will be analyzed according to their randomized 
treatment. 
The ITT will be used for summaries and analysis of disposition, demographics and baseline 
characteristics, and prior and concomitant medications. 
 
4.3. Safety Population 
The Safety population will consist of all subjects in the ITT population who received at least 
one dose of IP. Safety analyses will be analyzed according to their treatment received. 
The Safety population will be used for all safety analyses.  


Statistical Analysis Plan Version 1.0 
 
CONFIDENTIAL 
 
 
Protocol Reference: SBI-SB121-20-01 
 
 
Final, Version 1.0, 20Jan2022 
Page 10 of 28 
 
 
ST-AD-008 version 06 
 
5. Data Handling 
5.1. Time Points and Visit Windows 
5.1.1. General Definitions 
First dose date in Treatment Period 1 will be considered relative day 1, and the day before the 
first dose in Treatment Period 1 will be relative day -1.  Relative days will be calculated as 
follows only when the full assessment date is known: 
For days on or after the first dose in Treatment Period 1: 
Date of Assessment – Period 1 First Dose Date + 1. 
For days before the first dose in Treatment Period 1: 
Date of Assessment – Period 1 First Dose Date. 
 
5.1.2. Screening / Baseline Period 
For all subjects, the screening period will be defined as the period from informed consent to 
the first dose of treatment in Treatment Period 1.   
Baseline values for analyses of Treatment Period 1 will be the last observation prior to dosing 
in Period 1. Baseline values for analyses of Treatment Period 2 will be the last observation 
after the Treatment Period 1 washout and prior to dosing in Treatment Period 2. An additional 
analysis will be done for change of certain parameters,  as discussed in Section 6.1, to the end 
of Treatment Period 1  and to the end of Treatment Period 2, respectively, utilizing as Baseline 
values the last observation prior to dosing in Treatment Period 1. This will be done for each 
treatment group.  
 
 
5.1.3. Treatment Period 
There will be 2 treatment periods. The Treatment Period 1 will be defined as the period from 
the date/time of the first dose of treatment (Visit 1/Day 1) and up to and including the date of 
Visit 2/Day 28. Following Treatment Period 1 will be a washout period occurring for 
approximately 14 days. The Treatment Period 2 will be defined as the period from the 
date/time of first dose of cross-over treatment (Visit 3/Day 42) and up to and including the 
date of Visit 4/Day 70.  If the time (HH:MM) of data collection is not recorded but the protocol 
and / or eCRF includes an instruction to the effect that all Period 1 Day 1 and Period 2 Day 1 
assessments are to be performed prior to the first dose of treatment in the study period, the 
data collected at Day 1 will be assigned to the baseline period of the respective period.  
However, adverse events with missing time starting on Day 1 and medications starting on 
Day 1 of each period, will be assigned to the respective treatment period. 
 


Statistical Analysis Plan Version 1.0 
 
CONFIDENTIAL 
 
 
Protocol Reference: SBI-SB121-20-01 
 
 
Final, Version 1.0, 20Jan2022 
Page 11 of 28 
 
 
ST-AD-008 version 06 
 
5.1.4. Visit Windows 
All data will be analyzed using nominal study visit as defined in the Study Schedule per the 
protocol and eCRF. No visit windows will be applied for summary and analysis. 
 
5.2. Handling of Dropouts, Missing Data, and Outliers 
5.2.1. Handling of Missing Efficacy Data 
Not applicable 
5.2.2. Handling of Missing Safety Data 
Drop-outs will not be replaced in this study.  
In general, missing clinical laboratory data, vital signs,  and ECG data will not be imputed.  
Adverse event imputations for missing severity or relationship are given in Section 6.7.2.  
Unknown or partial medication and AE date imputations are given below and to be used only 
for the assessment of prior / concomitant status for medications and treatment-emergent status 
for AEs. 
5.2.3. Handling of Partial and Missing Dates for Adverse Events, Prior / Concomitant 
Medications 
Missing or Partial Adverse Event and Prior / Concomitant Medication Start Dates 
Missing and / or incomplete dates for medications and AEs are imputed in a manner resulting 
in the earliest onset or the longest duration during the study up until 14 days after study 
treatment, whilst ensuring that the start date does not occur after the stop date.  The stop date 
will not be imputed if the medication or AE is “Ongoing”. Technically, this imputation will 
be done as follows: 
 
For a missing / incomplete start date the earliest date of the following will be imputed: 
 The later date of: the earliest possible start date, and the date of first dose of treatment. 
 The latest possible start date. 
 The latest possible stop date. 
 
For a missing / incomplete stop date the later date of the following will be imputed: 
 The earlier date of the latest possible stop date and the date of last dose of treatment. 
 The earliest possible stop date. 
 The earliest possible start date. 
 


Statistical Analysis Plan Version 1.0 
 
CONFIDENTIAL 
 
 
Protocol Reference: SBI-SB121-20-01 
 
 
Final, Version 1.0, 20Jan2022 
Page 12 of 28 
 
 
ST-AD-008 version 06 
 
Here, the earliest possible date is defined as: 
 The date itself if available. 
 The date of the first day of the month at 00:00hrs, if month and year are available but 
the day is missing. 
 The date of the first day of the year at 00:00hrs, if year is available but day and month 
are missing. 
 00:00hrs on the day of informed consent, if the date is completely missing. 
 
The latest possible date / time is defined as: 
 The date itself if available. 
 The date of the last day of the month at 23:59hrs, if month and year are available but 
the day is missing.  
 The date of the last day of the year at 23:59hrs, if year is available but day and month 
are missing. 
 23:59hrs on the date of last known date on the study for the subject plus one year, if 
the date is completely missing. 


Statistical Analysis Plan Version 1.0 
 
CONFIDENTIAL 
 
 
Protocol Reference: SBI-SB121-20-01 
 
 
Final, Version 1.0, 20Jan2022 
Page 13 of 28 
 
 
ST-AD-008 version 06 
 
6. Statistical Methods 
 
6.1. General Principles 
For the purposes of this SAP, all data processing, summarization and analyses will be 
performed using 
 Drug Development’s SAS Environment / Version 9.4 (or later) of 
the SAS statistical software package.  When summarizing data by treatment group, results 
will be combined across the study periods.  For example, the data from subjects who received 
SB-121 in Treatment Period 1 will be combined with the data from subjects who received SB-
121 in Treatment Period 2. An additional analysis will be done for change of certain 
parameters to end of Treatment Period 1 and end of Treatment Period 2, respectively, utilizing 
as Baseline values the last observation prior to dosing in Treatment Period 1. This will be 
done for each treatment group. These parameters may include fecal calprotectin and 
lactoferrin, serum hs-CRP and tumor necrosis factor-α, and plasma oxytocin and vasopressin 
levels. 
 
The default summary statistics for quantitative variables will be the number of observations 
(n), mean, standard deviation (SD), median, minimum (min) and maximum (max), for those 
subjects with data. 
 
For qualitative variables, the number (n) and percentage (%) of subjects with non-missing 
data per category will be the default summary presentation, and where appropriate and 
present, the number of missing values as a “Missing” category. Number of subjects in the 
analysis population will be used as denominator for percentages calculation, unless stated 
otherwise in TFLs mock shell(s). 
 
For the TFLs, the laboratory results will be summarized or presented in International System 
of Units (SI) units.  
 
Specifications for table, figures and data listing formats can be found in the TFL shells 
specifications for this study. Please refer to “2. General Format Guidelines” section within 
TFL shells for more details on presentation of results. 
 
6.2. Subject Disposition and Data Sets Analyzed 
Subject disposition will be summarized by treatment sequence for the ITT population. The 
following information will be reported:  
 Number and percentage of screened subjects and reasons for screen failure. 
 Number and percentage of subjects for the following categories: 
o Randomized, 


Statistical Analysis Plan Version 1.0 
 
CONFIDENTIAL 
 
 
Protocol Reference: SBI-SB121-20-01 
 
 
Final, Version 1.0, 20Jan2022 
Page 14 of 28 
 
 
ST-AD-008 version 06 
 
o Treated in Period 1, 
o Not Treated in Period 1, 
o Completed Treatment in Period 1, 
o Discontinued Treatment in Period 1, 
o Reasons for Treatment discontinuation in Period 1, 
o Treated in Period 2, 
o Not Treated in Period 2, 
o Completed Treatment in Period 2, 
o Discontinued Treatment in Period 2, 
o Reasons for Treatment discontinuation in Period 2, 
o Completed the study,  
o Discontinued the Study, 
o Reasons for study discontinuation. 
 Number and percentage of subjects included in each study population 
 
A subject will be regarded as having completed the study if Disposition – End of Study eCRF 
response to ’Did the subject complete the study?’ is Yes. A subject will be considered as 
having discontinued the study if they have an eCRF response to ’Did the subject complete the 
study?’ of No. Otherwise, the subject will be considered as ongoing in the study. 
 
A listing of all subjects with their treatment and study completion status, including the 
respective reasons for treatment and study discontinuation will be presented for the ITT 
population. 
 
A listing of all screen failed subjects with their reasons for screen failure will be presented for 
all subjects.  A separate listing of subjects who failed at least one inclusion / exclusion criteria 
including a text description of the criterion failed will be presented for all subjects. 
 
A listing of all randomized subjects with their randomization details, including first dose date 
and actual treatment received will be presented for the ITT population. 
 
A listing of all subjects excluded from at least one analysis population will be presented for 
the All Screened population.  
 
6.3. Protocol Deviations 
All major protocol deviations will be summarized for the ITT population by treatment group 
as described below: 


Statistical Analysis Plan Version 1.0 
 
CONFIDENTIAL 
 
 
Protocol Reference: SBI-SB121-20-01 
 
 
Final, Version 1.0, 20Jan2022 
Page 15 of 28 
 
 
ST-AD-008 version 06 
 
 The number of unique subjects with at least one major protocol deviation as well as 
the number of subjects in each major protocol deviation category will be presented by 
descriptive summary statistics.  
 
A listing of all subjects with one or more protocol deviations will be presented for the ITT 
population.   
 
6.4. Demographic and Other Baseline Characteristics 
6.4.1. Demographic Characteristics 
Demographic characteristics will be summarized for the ITT population by treatment 
sequence and overall as described below. All missing data will be presented as part of a 
missing category, if appropriate.  Standard descriptive statistics will be presented for the 
continuous variables of: 
 Age (years) 
 Height (cm) at baseline 
 Weight (kg) at baseline 
 Body mass index (kg/m2) at baseline 
 
Total counts and percentages of subjects will be presented for the categorical variables of: 
 Sex 
 Race 
 Ethnicity 
 
Demographic characteristics will be listed for the ITT population. 
 
6.4.2. Baseline Characteristics 
Baseline characteristics will be summarized for the ITT by treatment sequence and overall as 
described below. All missing data will be presented as part of a missing category, if 
appropriate. 
 
Total counts and percentages of subjects will be presented for the categorical variables of: 
 ADOS-2 Score at Screening 
 DSM-5 checklist at Screening 
 Pregnancy test results at Screening 
 Drug of abuse at Screening per the urine drug screen 
 


Statistical Analysis Plan Version 1.0 
 
CONFIDENTIAL 
 
 
Protocol Reference: SBI-SB121-20-01 
 
 
Final, Version 1.0, 20Jan2022 
Page 16 of 28 
 
 
ST-AD-008 version 06 
 
No formal tests of statistical significance will be performed on the demographic and baseline 
characteristics data. 
 
Baseline characteristics will be listed for the ITT population. 
 
6.4.3. Medical History 
Medical history is defined as any condition, with the exception of the study indication, that 
the subject may have had prior to enrollment in the study, including any chronic conditions 
diagnosed prior to entry in the study.  
 
Medical history will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA) [version 24.0] and will be presented by System Organ Class (SOC) and Preferred 
Term (PT). Medical history will be sorted alphabetically by SOC and descending frequency 
of PT. 
Medical history records will be summarized for the ITT population by treatment sequence 
and overall. 
Medical history records will be listed by-subject and within-subject by medical history start 
date for the ITT population. 
 
6.4.4. Prior and Concomitant Medications 
All medications will be coded using the WHO Drug Global Dictionary, B3 Sep 2021, 
Anatomical Therapeutic Chemical (ATC) Classification codes. 
Prior medications and concomitant medications are defined as follows: 
 Prior medications are those that started prior to the start of dosing in  Treatment Period 
1. 
 Concomitant medications are those with a start date on or after the start of dosing in  
Treatment Period 1, or those with a start date before the start of dosing in Treatment 
Period 1 and either a stop date after the start of the Treatment Period 1 or are ongoing 
during the study. 
 If a medication starts prior to dosing in Treatment Period 1 and continues after dosing 
in Treatment Period 1 has started, it will be considered both prior and concomitant. 
 
See Section 5.2.3 for imputation of missing or partial dates for medication.   
 
Prior medications will be summarized for the ITT population by treatment sequence and 
overall, and concomitant medications will be summarized separately for the ITT population 
by treatment group as follows: 


Statistical Analysis Plan Version 1.0 
 
CONFIDENTIAL 
 
 
Protocol Reference: SBI-SB121-20-01 
 
 
Final, Version 1.0, 20Jan2022 
Page 17 of 28 
 
 
ST-AD-008 version 06 
 
 The number and percentage of subjects with at least one prior/concomitant medication 
will be presented. 
 The number and percentage of subjects with at least one prior/concomitant medication 
within each Anatomical Group (ATC Level 1) and preferred term will be presented. 
The summary will be sorted using numerical counts by descending order of 
Anatomical Group, then descending order of preferred term in the total column. Where 
groups or terms tie these will be sorted alphabetically. 
 
Prior medications and concomitant medications will be listed separately for the ITT 
population.  In the listings, the relative start and stop day of prior medication use will be 
calculated relative to the first dose date of Treatment Period 1.  In the listings, the relative 
start and stop day of concomitant medication use will be calculated relative to the first dose 
date of treatment in the period when the medication started and will be presented for those 
subjects who received at least one dose of treatment.  Only original dates will be presented in 
the listing even though the relative day may be based on an imputed date. 
 
6.5. Measurements of Treatment Compliance 
Treatment compliance is defined as the number of doses that were actually taken relative to 
the number of doses that should have been taken as per the protocol for the duration of actual 
treatment exposure.  
In general, the percentage overall compliance, assessed by dose count for each Treatment 
Period, will be calculated as follows: 
Compliance (%) = 
(Number of kits dispensed - Number of kits returned) 
 100% 
Number of days on treatment  Number of kits prescribed per day 
 
Number of days on treatment will be calculated as follows: 
(last dose date of treatment in a Treatment Period- first dose date of treatment in a 
Treatment Period) +1 
The calculated percentage compliance will be categorized as: 
 < 80% compliance 
 ≥ 80% compliance 
Compliance will be summarized for the ITT population by treatment group as follows: 
 Percent compliance will be presented by summary statistics.  
 Number and percentage of subjects within each of the compliance categories will be 
presented. Any subjects with missing data will be presented as part of a “Missing” 
category. 
Treatment compliance will be listed together with exposure for the ITT population.  Missing 
data will not be imputed and only original data for those fields (for example, date fields) will 
be presented in the listing together with derived variables such as the calculated compliance 
(%) and exposure duration.  




Statistical Analysis Plan Version 1.0 
 
CONFIDENTIAL 
 
 
Protocol Reference: SBI-SB121-20-01 
 
 
Final, Version 1.0, 20Jan2022 
Page 19 of 28 
 
 
ST-AD-008 version 06 
 
Plasma oxytocin and vasopressin levels will also be analyzed.  In accordance with the baseline 
value definition in Section 5.1.2, the absolute change from baseline will be derived as follows:  
Absolute change (unit) = (post-baseline value – baseline value) 
The following will be summarized by treatment group for the ITT population: 
  Observed values and percentage change from baseline at each assessed visit, 
including comparison of baseline to end of Treatment Period 1 and baseline to end of 
Treatment Period 2, for each parameter using summary statistics for continuous 
variables; 
A listing of all plasma oxytocin and vasopressin data including derived change from baseline 
will be provided for the ITT population. 
 
6.7. Safety 
6.7.1. Extent of Exposure 
Duration of exposure will be defined in days for each Treatment Period as: 
Exposure (days) = [date of last dose in a Treatment Period– date of first dose in a Treatment 
Period] + 1 – off-treatment days 
 
Duration of exposure will be summarized for the Safety population by treatment group 
using descriptive statistics. 
 
A listing of overall treatment exposure data, including the first and last dates of treatment 
will be presented together with compliance for the Safety population.  
 
6.7.2. Adverse Events 
All AEs recorded on the eCRF will be coded using the MedDRA dictionary [version 24.0] 
and classified as either pre-treatment AEs or treatment–emergent AEs (TEAEs) as follows: 
 Pre-treatment AEs are events that start prior to the start of Treatment Period 1. 
 TEAEs are either events with start date after the start of the Treatment Period 1 
(during or after the first dose of IP), or events with start date prior to the start of the 
Treatment Period whose severity worsens on or after the start of the Treatment 
Period (during or after the first dose of IP).  A TEAE occurring on or after the first 
dose of treatment in Treatment Period 1 up until the first dose of treatment in 
Treatment Period 2 will be assigned to the treatment group received in Treatment 
Period 1.  A TEAE occurring on or after the first dose of treatment in Treatment 
Period 2 up until the end of study will be assigned to the treatment group received 
in Treatment Period 2.  


Statistical Analysis Plan Version 1.0 
 
CONFIDENTIAL 
 
 
Protocol Reference: SBI-SB121-20-01 
 
 
Final, Version 1.0, 20Jan2022 
Page 20 of 28 
 
 
ST-AD-008 version 06 
 
 Treatment-Emergent Serious AEs (TESAEs) will be defined as TEAEs regarded by 
the investigator as Serious = “Yes”. 
 The relationship between a TEAE and SB-121 is assessed as definitely, probably, 
possibly, unlikely, or not related. A treatment-related TEAE will be defined as a 
TEAE considered by the investigator as definitely, probably, or possibly related to 
treatment or with unknown / missing relationship to treatment. 
 Assessment of AE severity / intensity will be based on the National Cancer Institute-
Common Terminology Criteria for AEs (NCI-CTCAE2, version 5.0). If an NCI-
CTCAE scale is not available for a given AE, the following definitions will be used: 
 Grade 
1 
(mild) 
 asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated. 
 Grade 
2 
(moderate) 
 minimal, local or noninvasive intervention indicated; 
limiting age appropriate instrumental activities of daily 
living 
 Grade 
3 
(severe) 
 medically 
significant 
but 
not 
immediately 
life-
threatening; 
hospitalization 
or 
prolongation 
of 
hospitalization indicated; disabling; limiting self-care 
activities of daily living 
 Grade 
4 
(life-
threatening) 
 Life-threatening 
consequences; 
urgent 
intervention 
indicated 
 
 Grade 5 
 Death related to AE 
 
In addition to the aforementioned AE types, TEAEs of special interest will be identified as 
collected in the eCRF. 
 
Adverse events will be summarized by descriptive summary statistics for categorical variables 
for the Safety population by treatment group as follows: 
 An overview of TEAEs including the number and percentage of subjects with at least 
one TEAE type. 
o Any TEAE 
 TEAEs of Special Interest 
 Leading to discontinuation of study treatment 
 Leading to death 
 Grade 1 severity (mild) 
 Grade 2 severity (moderate) 
 Grade 3 severity (severe) 
 Grade 4 severity (life-threatening) 


Statistical Analysis Plan Version 1.0 
 
CONFIDENTIAL 
 
 
Protocol Reference: SBI-SB121-20-01 
 
 
Final, Version 1.0, 20Jan2022 
Page 21 of 28 
 
 
ST-AD-008 version 06 
 
 Grade 5 severity (death) 
o Any study treatment related TEAE 
 Leading to discontinuation of study treatment 
 Leading to death 
o Any serious TEAE 
 Leading to discontinuation of study treatment 
 Leading to death 
o Any serious study treatment related TEAE 
 Leading to discontinuation of study treatment 
 Leading to death 
 The number and percentage of subjects reporting each TEAE and the count of number 
of events will be summarized by SOC and PT for the following types of TEAEs: 
o TEAEs of Special Interest 
o TEAEs Leading to Interruption of Study Treatment 
o TEAEs Leading to Discontinuation of Study Treatment 
o TEAEs Leading to Death 
o TEAEs by Maximum Severity 
o TEAEs that are Related to Study Treatment 
o Serious TEAEs 
o Serious TEAEs that are Related to Study Treatment 
In the above summaries, subjects with more than one TEAE within a particular SOC are 
counted only once for that SOC. Similarly, subjects with more than one TEAE within a 
particular PT are counted only once for that PT. 
 
For summaries by maximum severity, subjects with multiple TEAEs within a particular SOC 
or PT will be counted under the category of their most severe TEAE within that SOC or PT.   
TEAEs with missing severity will be included in the counts of the ‘Number of Subjects with 
at least one TEAE’, ‘System Organ Class’ and ‘Preferred Term’ rows of the summary but 
they will not be included in the counts by severity. 
 
Summaries by SOCs and PTs will be sorted by SOCs and PTs within SOC by descending 
order of total incidence in the active treatment group. Where preferred terms tie PTs will be 
sorted alphabetically. 
No statistical comparisons of AEs between treatment groups will be performed. 
 
All AE data will be listed and Pre-treatment AEs and TEAEs will be presented together. 
Treatment-emergence status will be flagged in the listing. The listing will present the relative 
start and stop day of the AE calculated relative to the first dose of treatment in the Treatment 
Period when the AE started and will be presented for those subjects who received at least one 
dose of treatment. Only original dates will be presented in the listing even though the relative 
day may be based on an imputed date. 


Statistical Analysis Plan Version 1.0 
 
CONFIDENTIAL 
 
 
Protocol Reference: SBI-SB121-20-01 
 
 
Final, Version 1.0, 20Jan2022 
Page 22 of 28 
 
 
ST-AD-008 version 06 
 
In addition, the following listings will be presented: 
 Listing of Deaths 
 Listing of Serious TEAEs 
 Listing of AEs Leading to Interruption of Study Treatment 
 Listing of AEs Leading to Discontinuation of Study Treatment 
 Listing of AEs of Special Interest 
 
6.7.3. Laboratory Evaluations 
Data for the following hematology, biochemistry, and urinalysis analytes recorded in the 
eCRF are to be measured at the scheduled visits. 
Hematology:  
hemoglobin, hematocrit, red blood cell (RBC) 
count, mean corpuscular hemoglobin, mean 
corpuscular volume, mean corpuscular hemoglobin 
concentration, platelet count, white blood cell 
count including differential (to also include 
absolute neutrophil, lymphocyte and eosinophil 
counts)  
Serum Chemistry:  
albumin, total and direct bilirubin, total protein, 
calcium, alkaline phosphatase, alanine 
aminotransferase, aspartate aminotransferase, blood 
urea nitrogen, creatinine, glucose, sodium, 
potassium, chloride, bicarbonate, lactate 
dehydrogenase, uric acid, highly sensitive C-
reactive protein  
Urinalysis (dipstick):  
pH, specific gravity, blood, glucose, protein, 
ketones  
  
In accordance with the baseline value definition in Section 5.1.2, the absolute change from 
baseline will be derived for quantitative data as follows:  
Absolute change (unit) = (post-baseline value – baseline value) 
 
All laboratory data will be reported in SI units. Categorization of abnormal laboratory results 
along with clinical significance will be collected in a spreadsheet outside of the EDC database 
and  utilized for the below outlined analysis. The same data (abnormal values) collected within 
the EDC will not be used in any statistical analysis. All normal results will continue to be 
collected and presented from the EDC. All quantitative laboratory test values at each assessed 
visit will be compared with the relevant reference range in SI units and categorized as: 
o Low: Below the lower limit of the reference range.  
o Normal: Within the reference range (upper and lower limits included). 
o High: Above the upper limit of the reference range.  


Statistical Analysis Plan Version 1.0 
 
CONFIDENTIAL 
 
 
Protocol Reference: SBI-SB121-20-01 
 
 
Final, Version 1.0, 20Jan2022 
Page 23 of 28 
 
 
ST-AD-008 version 06 
 
For summaries which present worst value with respect to the reference range at the subject 
level, low and high are each chosen in preference to normal values. For parameters with values 
that are both low and high, subjects will be counted within each category for worst value 
summary tables. 
 
 
Laboratory data will be summarized by descriptive summary statistics for continuous and 
categorical variables for the Safety population by treatment group as follows: 
  Observed values and  change from baseline for each Treatment Period at each 
assessed visit for each standard continuous laboratory parameter; 
 Number and percentage of subjects with categorized shift (low, normal, and high) 
values relative to the reference range at baseline compared to each post-baseline at 
each visit for each Treatment Period 
 Number and percentage of subjects with worst categorized (low, normal, and high) 
values relative to the reference range; 
 
Listings of all clinical laboratory data including derived change from baseline will be provided 
for the Safety population. Within each listing, laboratory values outside the normal ranges 
flagged as either high or low will be provided for applicable laboratory assessments.  Listings 
of pregnancy results will also be provided for the Safety population. 
 
6.7.4. Vital Signs 
The analyses described below will be conducted for the following vital signs assessments 
respectively: 
 systolic blood pressure (mmHg); 
 diastolic blood pressure (mmHg); 
 pulse rate (bpm); 
 body temperature (°C). 
 
In accordance with the baseline value definition in Section 5.1.2, the absolute change from 
baseline will be derived as follows:  
Absolute change (unit) = (post-baseline value – baseline value) 
The following will be summarized by treatment group for the Safety population: 
  Observed values and percentage change from baseline at each assessed visit for each 
standard vital sign parameter using summary statistics for continuous variables; 
A listing of all vital signs data including derived percentage change from baseline will be 
provided for the Safety population. 
 


Statistical Analysis Plan Version 1.0 
 
CONFIDENTIAL 
 
 
Protocol Reference: SBI-SB121-20-01 
 
 
Final, Version 1.0, 20Jan2022 
Page 24 of 28 
 
 
ST-AD-008 version 06 
 
6.7.5. Electrocardiograms 
The following electrocardiogram (ECG) assessments will be taken during the study: 
 An overall investigator assessment classified as normal, abnormal, not clinically 
significant / abnormal, clinically significant 
 Heart rate (bpm); 
 RR interval (msec); 
 PR interval (msec); 
 QRS interval (msec); 
 QT interval (msec); 
 QTcB interval (msec). 
 
In accordance with the baseline value definition in Section 5.1.2, the absolute change from 
baseline will be derived as follows:  
Absolute change (unit) = (post-baseline value – baseline value) 
 
The ECG findings will be summarized by treatment group for the Safety population as 
follows: 
 Observed values and percentage change from baseline at each assessed visit for each 
ECG parameter using summary statistics for continuous variables; 
 The ECG overall assessment as reported by the investigator will be summarized at 
each assessed visit by providing number and percentage of subjects within each 
assessment category; 
 
A listing of all ECG data will be provided for the Safety population. 
 
6.7.6. Physical Examination 
For each physical examination body system, the number and percentage of subjects with 
abnormalities at baseline and at each assessed visit will be summarized by treatment group 
for the Safety population. 
Physical examination findings (normal / abnormal) and details of abnormalities will be listed 
for each subject at each assessed visit for the Safety population. 
 
 
6.7.7. Interim Analysis and Data Monitoring 
No interim analysis and data monitoring is planned for this study. 
 


Statistical Analysis Plan Version 1.0 
 
CONFIDENTIAL 
 
 
Protocol Reference: SBI-SB121-20-01 
 
 
Final, Version 1.0, 20Jan2022 
Page 25 of 28 
 
 
ST-AD-008 version 06 
 
6.8. Pharmacokinetic Assessments  
No PK assessments are planned for this study.  
 


Statistical Analysis Plan Version 1.0 
 
CONFIDENTIAL 
 
 
Protocol Reference: SBI-SB121-20-01 
 
 
Final, Version 1.0, 20Jan2022 
Page 26 of 28 
 
 
ST-AD-008 version 06 
 
7. Changes in the Conduct of the Study or Planned Analysis 
There were no changes in the conduct of the study at the time of preparing this SAP.  There 
were no changes in the analysis planned in the protocol of the study at the time of preparing 
this SAP. 
 
 
 




Statistical Analysis Plan Version 1.0 
 
CONFIDENTIAL 
 
 
Protocol Reference: SBI-SB121-20-01 
 
 
Final, Version 1.0, 20Jan2022 
Page 28 of 28 
 
 
ST-AD-008 version 06 
 
8. References 
1ICH. Structure and Content of Clinical Study Reports, Guideline E3, 1995. Available at  
https://database.ich.org/sites/default/files/E3_Guideline.pdf 
 
2Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Available at 
https://ctep.cancer.gov/protocolDevelopment/electronic applications/ctc.htm#ctc 50